176 related articles for article (PubMed ID: 16302826)
1. Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists.
Quattropani A; Dorbais J; Covini D; Pittet PA; Colovray V; Thomas RJ; Coxhead R; Halazy S; Scheer A; Missotten M; Ayala G; Bradshaw C; De Raemy-Schenk AM; Nichols A; Cirillo R; Tos EG; Giachetti C; Golzio L; Marinelli P; Church DJ; Barberis C; Chollet A; Schwarz MK
J Med Chem; 2005 Dec; 48(24):7882-905. PubMed ID: 16302826
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
Cirillo R; Gillio Tos E; Schwarz MK; Quattropani A; Scheer A; Missotten M; Dorbais J; Nichols A; Borrelli F; Giachetti C; Golzio L; Marinelli P; Thomas RJ; Chevillard C; Laurent F; Portet K; Barberis C; Chollet A
J Pharmacol Exp Ther; 2003 Jul; 306(1):253-61. PubMed ID: 12660315
[TBL] [Abstract][Full Text] [Related]
3. SSR126768A (4-chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, hydrochloride): a new selective and orally active oxytocin receptor antagonist for the prevention of preterm labor.
Serradeil-Le Gal C; Valette G; Foulon L; Germain G; Advenier C; Naline E; Bardou M; Martinolle JP; Pouzet B; Raufaste D; Garcia C; Double-Cazanave E; Pauly M; Pascal M; Barbier A; Scatton B; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 2004 Apr; 309(1):414-24. PubMed ID: 14722330
[TBL] [Abstract][Full Text] [Related]
4. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokinetics.
Borthwick AD; Davies DE; Exall AM; Livermore DG; Sollis SL; Nerozzi F; Allen MJ; Perren M; Shabbir SS; Woollard PM; Wyatt PG
J Med Chem; 2005 Nov; 48(22):6956-69. PubMed ID: 16250654
[TBL] [Abstract][Full Text] [Related]
5. Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.
Chan WY; Wo NC; Cheng LL; Manning M
J Pharmacol Exp Ther; 1996 May; 277(2):999-1003. PubMed ID: 8627583
[TBL] [Abstract][Full Text] [Related]
6. 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency.
Borthwick AD; Davies DE; Exall AM; Hatley RJ; Hughes JA; Irving WR; Livermore DG; Sollis SL; Nerozzi F; Valko KL; Allen MJ; Perren M; Shabbir SS; Woollard PM; Price MA
J Med Chem; 2006 Jul; 49(14):4159-70. PubMed ID: 16821776
[TBL] [Abstract][Full Text] [Related]
7. Vasopressin and oxytocin in normal reproduction and in the pathophysiology of preterm labour and primary dysmenorrhoea. Development of receptor antagonists for therapeutic use in these conditions.
Akerlund M
Rocz Akad Med Bialymst; 2004; 49():18-21. PubMed ID: 15631309
[TBL] [Abstract][Full Text] [Related]
8. Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.
Scott JD; Miller MW; Li SW; Lin SI; Vaccaro HA; Hong L; Mullins DE; Guzzi M; Weinstein J; Hodgson RA; Varty GB; Stamford AW; Chan TY; McKittrick BA; Greenlee WJ; Priestley T; Parker EM
Bioorg Med Chem Lett; 2009 Nov; 19(21):6018-22. PubMed ID: 19800231
[TBL] [Abstract][Full Text] [Related]
9. Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.
McCafferty GP; Pullen MA; Wu C; Edwards RM; Allen MJ; Woollard PM; Borthwick AD; Liddle J; Hickey DM; Brooks DP; Westfall TD
Am J Physiol Regul Integr Comp Physiol; 2007 Jul; 293(1):R299-305. PubMed ID: 17395790
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
[TBL] [Abstract][Full Text] [Related]
11. Development of orally active oxytocin antagonists: studies on 1-(1-[4-[1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy]-2- methoxybenzoyl]piperidin-4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines.
Bell IM; Erb JM; Freidinger RM; Gallicchio SN; Guare JP; Guidotti MT; Halpin RA; Hobbs DW; Homnick CF; Kuo MS; Lis EV; Mathre DJ; Michelson SR; Pawluczyk JM; Pettibone DJ; Reiss DR; Vickers S; Williams PD; Woyden CJ
J Med Chem; 1998 Jun; 41(12):2146-63. PubMed ID: 9622556
[TBL] [Abstract][Full Text] [Related]
12. Arrest of preterm labor in rat and mouse by an oral and selective nonprostanoid antagonist of the prostaglandin F2alpha receptor (FP).
Cirillo R; Tos EG; Page P; Missotten M; Quattropani A; Scheer A; Schwarz MK; Chollet A
Am J Obstet Gynecol; 2007 Jul; 197(1):54.e1-9. PubMed ID: 17618756
[TBL] [Abstract][Full Text] [Related]
13. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
14. Profile of an oxytocin antagonist, RWJ 22164 for treatment of preterm labor in laboratory models of uterine contractility.
Demarest KT; Hahn DW; Ericson E; Capetola RJ; Fuchs AR; McGuire JL
Am J Perinatol; 1989 Apr; 6(2):200-4. PubMed ID: 2712917
[TBL] [Abstract][Full Text] [Related]
15. Barusiban suppresses oxytocin-induced preterm labour in non-human primates.
Reinheimer TM
BMC Pregnancy Childbirth; 2007 Jun; 7 Suppl 1(Suppl 1):S15. PubMed ID: 17570159
[TBL] [Abstract][Full Text] [Related]
16. Introduction of a cis-prolyl mimic in position 7 of the peptide hormone oxytocin does not result in antagonistic activity.
Wittelsberger A; Patiny L; Slaninova J; Barberis C; Mutter M
J Med Chem; 2005 Oct; 48(21):6553-62. PubMed ID: 16220972
[TBL] [Abstract][Full Text] [Related]
17. Progress in the development of oxytocin antagonists for use in preterm labor.
Williams PD; Bock MG; Evans BE; Freidinger RM; Pettibone DJ
Adv Exp Med Biol; 1998; 449():473-9. PubMed ID: 10026841
[TBL] [Abstract][Full Text] [Related]
18. Oxytocin and vasopressin V(1A) receptors as new therapeutic targets in assisted reproduction.
Pierzynski P
Reprod Biomed Online; 2011 Jan; 22(1):9-16. PubMed ID: 21130036
[TBL] [Abstract][Full Text] [Related]
19. Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.
Murugesan N; Gu Z; Spergel S; Young M; Chen P; Mathur A; Leith L; Hermsmeier M; Liu EC; Zhang R; Bird E; Waldron T; Marino A; Koplowitz B; Humphreys WG; Chong S; Morrison RA; Webb ML; Moreland S; Trippodo N; Barrish JC
J Med Chem; 2003 Jan; 46(1):125-37. PubMed ID: 12502366
[TBL] [Abstract][Full Text] [Related]
20. Identification of an orally active, nonpeptidyl oxytocin antagonist.
Pettibone DJ; Clineschmidt BV; Kishel MT; Lis EV; Reiss DR; Woyden CJ; Evans BE; Freidinger RM; Veber DF; Cook MJ
J Pharmacol Exp Ther; 1993 Jan; 264(1):308-14. PubMed ID: 8423533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
